Capmatinib detailed instructions

Capmatinib (Capmatinib) is used to treat non-small cell lung cancer that has spread to other parts of the body (metastatic) or cannot be removed by surgery. Capmatinib is only used if your cancerhas a specific genetic marker (an abnormal "MET" gene). Your doctor will test you for this gene.

Mechanism of action:Abnormal activation of c-Met has been widely documented in many types of cancer, and non-small cell lung cancer (NSCLC) is one of them. MET exon 14-skipping mutations cause a situation in which c-Met mutants lack regulatory domains. The negative regulatory functions of these mutant proteins are impaired, resulting in pathological enhancement of their downstream activities. Capmatinib can effectively inhibit the phosphorylation process of wild-type and mutant c-Met, which is usually triggered by the binding of its endogenous ligand, hepatocyte growth factor. In this way, capmatinib can prevent c-Met-mediated phosphorylation of downstream signaling proteins, thereby inhibiting the proliferation and survival of c-Met-dependent tumor cells.

Dosage: Usual adult dose for non-small cell lung cancer:400 mg orally twice daily.

SIDE EFFECTS: If you develop symptoms of an allergic reaction, such as hives, difficulty breathing, or swelling of your face, lips, tongue, or throat, be sure to seek emergency medical help immediately.

Capmatinib may cause serious adverse reactions. Contact your doctor right away if you have: a new or worsening cough, chest pain, difficulty breathing; fever and coughing up phlegm; persistent and severe nausea and vomiting; or signs of liver or pancreatic problems, such as loss of appetite, upper abdominal pain (which may radiate to the back), nausea, vomiting, rapid heartbeat, dark urine, or jaundice (yellowing of the skin or whites of the eyes). If you develop certain adverse effects, your cancer treatment may be temporarily put on hold or permanently stopped.

After taking capmatinib, you may also experience the following common adverse reactions: difficulty breathing, nausea, vomiting, loss of appetite, general weakness or fatigue, abnormal liver function tests, or swelling of your hands and feet. Please note that this is not a complete list of adverse effects and other adverse effects may occur with taking this medicine.

PRECAUTIONS: Follow all directions on the drug label and packaging. Tell each of your doctors all of your medical conditions, allergies, and all the medications you take.

Tell your doctor if you have ever had: lung problems other than lung cancer; or liver disease.

You may need to have a negative pregnancy test before starting this treatment. Both men and women taking capmatinib should use effective birth control to prevent pregnancy. Capmatinib may harm an unborn baby if the mother or father uses this drug. Continue using birth control for at least 1 week after your last dose. If the mother or father becomes pregnant while taking capmatinib, tell your doctor right away. Do not breastfeed while you are using this medicine and for at least 1 week after your last dose.

Storage: Store at room temperature, away from moisture and heat. Store tablets in their original containers with hygroscopic preservative packets or jars.